Tamtam Try Tamtam free
IQVIA logo

IQVIA account plan

Clinical research health intelligence

At a glance

IQVIA provides clinical research, commercial insights and healthcare data to life-sciences firms, with FY2025 revenue of $16,310 million.

IQVIA sells clinical research services, commercial insights and healthcare data and technology to life-sciences companies, payers, governments and providers. It serves over 10,000 clients in over 100 countries, including nearly all of the top 100 pharmaceutical and biotech companies, and holds more than 1.2 billion non-identified patient records. FY2025 revenue was $16,310 million (up 5.9%), with net income attributable of $1,360 million and diluted EPS of $7.84; the United States provides approximately 42% of revenue. Headcount is approximately 94,000, and the company is led by Chairman and CEO Ari Bousbib.

Business units

Strategic priorities

Connected Intelligence and Healthcare-grade AI
Use proprietary data and domain expertise for AI; IQVIA has 294 agents deployed across 90 use cases and four of the top 10 pharma companies co-develop AI with it.
Deeper client relationships
Be a more complete partner across R&D and commercial; IQVIA increased the number and scope of large pharma preferred partnerships.
Expand into the broader healthcare market
Reach payers, providers, governments and NGOs, for example through Cedar Gate Technologies in U.S. payer analytics.
Acquisitions
$1,714 million spent on acquisitions in 2025, and Charles River discovery assets acquired in Q2 2026.
2026 guidance
Full-year 2026 revenue growth of 5.9% to 7.1%, adjusted EPS of $12.80 to $13 and an adjusted EBITDA margin of about 23.2%.

Latest results

In Q2 2026 revenue rose 8.7% to $4,368 million (8.5% at constant currency) and H1 revenue reached $8,519 million (+8.6%). Commercial Solutions grew 8.6% to $1,793 million with segment profit up 10.6%, and R&DS grew 8.8% to $2,575 million with segment profit up 11.2%. R&DS net new bookings were $3,150 million, the highest since 2022, for a book-to-bill of 1.22. Net income attributable was $256 million and diluted EPS $1.53, flat as restructuring and unallocated costs rose; adjusted EPS was $3.15 (+12.1%), and full-year guidance was raised.

Investments and deals

Acquisitions in 2025
$1,714 million invested across all three segments, including Cedar Gate Technologies and Next Oncology sites.
Charles River discovery assets
Acquisition completed in Q2 2026, expanding capabilities toward drug discovery.
AI with NVIDIA and AWS
Agents built with NVIDIA; AWS named as preferred agentic cloud provider.
Share buybacks
$950 million repurchased in H1 2026; total authorization raised to $15,725 million.
Restructuring
Actions to streamline operations and reduce overcapacity, now expected to continue throughout 2026 and into 2027.

Challenges and risks

AI disruption fears
Bousbib concedes some lower-level consulting and analytics work may be displaced.
Contract cancellations and backlog review
Clients can terminate on 30 to 90 days' notice, and a review of inactive trials may trim backlog by about 5%.
Data supply and privacy
Dependence on third-party data suppliers, cybersecurity and AI regulation such as the EU AI Act.
Leverage and costs
Total indebtedness of $16,081 million and net leverage of 3.59 times, with pass-through costs dragging margins.

What leadership says

“it's an opportunity, not a challenge”

Ari Bousbib, Chairman and CEO · Q4 and full year 2025 earnings call, 5 February 2026

“We sell the final product, not the ingredients.”

Ari Bousbib, Chairman and CEO · Q4 and full year 2025 earnings call, 5 February 2026

“some lower-level consulting and analytics work may be displaced”

Ari Bousbib, Chairman and CEO · Q4 and full year 2025 earnings call, 5 February 2026

Where a supplier can help

AI infrastructure and tooling
Scaling agents across use cases under the Healthcare-grade AI priority calls for model, compute, governance and data tooling partners.
Clinical site and lab capacity
Record R&DS bookings and large pharma requests for more capacity create demand for site networks, lab equipment and clinical staffing.
Data supply partnerships
Dependence on third-party data suppliers makes new healthcare data sources and data-quality providers relevant.
Integration of acquisitions
Integrating Cedar Gate and the Charles River discovery assets requires systems, finance and data integration support.
Cost and productivity programs
Ongoing restructuring and pass-through cost pressure point to automation and procurement solutions.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like IQVIA?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about IQVIA

What does IQVIA do?

IQVIA provides clinical research services, commercial insights and healthcare data and technology to life-sciences companies and the broader healthcare market.

What is IQVIA's revenue?

FY2025 revenue was $16,310 million, up 5.9%. Q2 2026 revenue was $4,368 million, up 8.7%.

How many employees does IQVIA have?

Approximately 94,000 employees in over 100 countries as of mid-2026.

Who leads IQVIA?

Ari Bousbib is Chairman and CEO; Mike Fedock is EVP and CFO.

What is IQVIA's strategy?

IQVIA grows through Connected Intelligence and Healthcare-grade AI, deeper client relationships, expansion into payers and providers, and acquisitions.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)